Because our science is life changing
We continuously build on our legacy as the leading radiopharmaceutical-focused company, enabling healthcare providers to Find, Fight and Follow® disease through the development of next-generation radiodiagnostics, targeted radiotherapeutics, and radiotheranostic pairs.
Finding and Fighting Disease at the Source
Radiopharmaceuticals are an essential component of nuclear medicine, harnessing the power of radioactive isotopes to advance precision diagnostic imaging and targeted therapeutics.
Radiodiagnostics administer radiotracers that localize in targeted tissue and, when used in conjunction with an imaging modality like positron emission tomography (PET), can help physicians diagnose, stage, and monitor disease.1
Radiotherapeutics combine targeting molecules, which seek out and bind to cancer cells, and radioisotopes to deliver a high dose of radiation to these cells while minimizing damage to healthy tissue.2
Radiotheranostics pair radiodiagnostics and radiotherapeutics that target the same molecules in tumors for improved diagnostic accuracy, treatment efficacy and monitoring of treatment response.
Our Focus Areas
At Lantheus, we are investigating several early- and late-stage innovative radiodiagnostic and radiotherapeutic candidates across our core disease areas of oncology and neurology.
Oncology
More than one third of all people will be diagnosed with cancer,3 creating a significant need for earlier diagnosis and targeted treatment to improve patient outcomes. We’re focused on complementary radiodiagnostic and radiotherapeutic pairs, called radiotheranostics.
Neurology
With approximately one in nine people over the age of 65 facing an Alzheimer’s diagnosis,4 our focus is on supporting earlier diagnosis, staging and monitoring of Alzheimer’s and other forms of dementia.
Cardiology
Early and accurate identification of cardiovascular disease is critical for timely intervention and improved patient outcomes.5 We’re exploring innovations in advanced molecular imaging for potential diagnostic applications.
The Future of Radiopharmaceuticals
The radiopharmaceutical market is predicted to experience rapid growth over the next decade.5 At Lantheus, we are building on our foundation as a leader in this space to power the future of radiopharmaceuticals and improve patient outcomes.
References: 1. Radiotracers Are Revolutionized with a Novel Method. National Institute of Biomedical Imaging and Bioengineering. Published November 22, 2019. Accessed May 21, 2025. https://www.nibib.nih.gov/news-events/newsroom/radiotracers-are-revolutionized-novel-method 2. EANM Position Paper. European Association of Nuclear Medicine. Published May 2024. Accessed May 21, 2025. https://eanm.org/wp-content/uploads/2024/05/EANM-overarching-narrative_0707.pdf 3. Cancer Statistics. National Cancer Institute. Published May 7, 2025. Accessed May 21, 2025. https://www.cancer.gov/about-cancer/understanding/statistics 4. Alzheimer’s Disease Facts and Figures. Alzheimer’s Association. Published 2025. Accessed May 21, 2025. https://www.alz.org/alzheimers-dementia/facts-figures 5. MEDraysintell 2024 Nuclear Medicine Report. MEDraysintell. Published October 9, 2024. Accessed May 21, 2025.